

# Krzysztof Simon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6242899/krzysztof-simon-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83  
papers

2,195  
citations

17  
h-index

45  
g-index

90  
ext. papers

2,685  
ext. citations

3.9  
avg, IF

4.5  
L-index

#	Paper	IF	Citations
83	HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
82	Liver Injury in Patients with COVID-19 without Underlying Liver Disease.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
81	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland.. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	3
80	Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , <b>2021</b> , 131,	1.9	1
79	When Conventional Oxygen Therapy Fails-The Effectiveness of High-Flow Nasal Oxygen Therapy in Patients with Respiratory Failure in the Course of COVID-19. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
78	Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. <i>Viruses</i> , <b>2021</b> , 13,	6.2	11
77	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	9
76	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. <i>Polish Archives of Internal Medicine</i> , <b>2021</b> , 131, 487-496	1.9	13
75	Value of quantitative analysis in lung computed tomography in patients severely ill with COVID-19. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251946	3.7	4
74	Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. <i>Cells</i> , <b>2021</b> , 10,	7.9	8
73	Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 2177-2192	5.6	1
72	The chest radiographic scoring system in initial diagnosis of COVID-19: Is a radiologist needed?. <i>Advances in Clinical and Experimental Medicine</i> , <b>2021</b> , 30, 797-803	1.8	0
71	Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
70	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	16
69	Lymphocyte subsets in haematological patients with COVID-19: Multicentre prospective study. <i>Translational Oncology</i> , <b>2021</b> , 14, 100943	4.9	6
68	The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	46
67	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 649-658	18.8	9

66	Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 438-446	2.2	2
65	Serum concentrations of selected adipokines in virus-related liver cirrhosis and hepatocellular carcinoma. <i>Clinical and Experimental Hepatology</i> , <b>2020</b> , 6, 235-242	2.2	2
64	Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA. <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 1045-1054	5.5	7
63	Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). <i>PLoS ONE</i> , <b>2020</b> , 15, e0227459	3.7	8
62	Usefulness of a portable chest radiograph in the initial diagnosis of coronavirus disease 2019. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 906-909	1.9	3
61	Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 163-172	1.9	9
60	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 352-357	1.9	26
59	Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 338-339	1.9	9
58	Rapid progression of inflammatory pulmonary infiltrates in severe acute respiratory syndrome coronavirus 2 infection in a young man. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 326-327	1.9	1
57	Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. <i>Polish Archives of Internal Medicine</i> , <b>2020</b> , 130, 915-918	1.9	14
56	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. <i>Kardiologia Polska</i> , <b>2020</b> , 78, 811-817	0.9	
55	Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1238-1246	4	7
54	Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. <i>Advances in Medical Sciences</i> , <b>2020</b> , 65, 12-17	2.8	3
53	Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. <i>Clinical and Experimental Hepatology</i> , <b>2020</b> , 6, 163-169	2.2	7
52	Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - High mortality rate in infected patients with haematologic malignancies. <i>Journal of Clinical Virology</i> , <b>2020</b> , 130, 104574	14.5	21
51	Searching for the optimal population for hepatitis C virus screening in Poland. <i>Clinical and Experimental Hepatology</i> , <b>2020</b> , 6, 74-76	2.2	0
50	Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1156-1163	3.4	10
49	Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 2019, 4029541	2.8	8

48	Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2). <i>Hepatology</i> , <b>2019</b> , 70, 1336-1348	11.2	74
47	Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 109-117	3.4	13
46	Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. <i>Journal of Interferon and Cytokine Research</i> , <b>2018</b> , 38, 93-100	3.5	6
45	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , <b>2018</b> , 67, 1754-1767	11.2	376
44	Interferon Free Therapy with and Without Ribavirin for Genotype 1 HCV Cirrhotic Patients in the Real World Experience. <i>Hepatitis Monthly</i> , <b>2018</b> , 18,	1.8	2
43	The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 580	4	1
42	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical and Experimental Hepatology</i> , <b>2018</b> , 4, 153-157	2.2	6
41	Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. <i>Advances in Medical Sciences</i> , <b>2017</b> , 62, 387-392	2.8	18
40	Recommendations for the treatment of hepatitis B in 2017. <i>Clinical and Experimental Hepatology</i> , <b>2017</b> , 3, 35-46	2.2	12
39	Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	1
38	The risk of complications of endoscopic procedures in patients with liver cirrhosis. <i>Clinical and Experimental Hepatology</i> , <b>2017</b> , 3, 135-140	2.2	7
37	Recommendations for the treatment of hepatitis C in 2017. <i>Clinical and Experimental Hepatology</i> , <b>2017</b> , 3, 47-55	2.2	24
36	Influence of Diabetes on Circulating Apoptotic Microparticles in Patients with Chronic Hepatitis C. <i>In Vivo</i> , <b>2017</b> , 31, 1027-1034	2.3	3
35	Nutrition principles and recommendations in different types of hepatic encephalopathy. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 1, 121-126	2.2	2
34	Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts - 2016. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 27-33	2.2	13
33	Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 138-143	2.2	12
32	Prevalence of HCV genotypes in Poland - the EpiTer study. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 144-148	2.2	13
31	Evaluation of hepatic fibrosis - access to non-invasive methods, national practice/guidelines in Central Europe. <i>Clinical and Experimental Hepatology</i> , <b>2016</b> , 2, 12-15	2.2	5

30	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. <i>Hepatology International</i> , <b>2016</b> , 10, 779-88	8.8	17
29	Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , <b>2015</b> , 61, 1512-22	11.2	124
28	Tissue laser biostimulation promotes post-extraction neoangiogenesis in HIV-infected patients. <i>Lasers in Medical Science</i> , <b>2015</b> , 30, 701-6	3.1	12
27	Manganese Encephalopathy among Ephedron Abusers. <i>Journal of Neuroimaging</i> , <b>2015</b> , 25, 832-5	2.8	8
26	Distribution of HBV genotypes in Poland. <i>Clinical and Experimental Hepatology</i> , <b>2015</b> , 1, 1-4	2.2	5
25	Recommendations for treatment of hepatitis C. Polish Group of HCV Experts - 2015. <i>Clinical and Experimental Hepatology</i> , <b>2015</b> , 1, 97-104	2.2	3
24	Diagnostic challenges in primary hepatocellular carcinoma: case reports and review of the literature. <i>Case Reports in Oncological Medicine</i> , <b>2015</b> , 2015, 878763	0.9	5
23	Impact of vaccination against HBV on hepatitis B incidence in Opolskie province in 2007-2011. <i>Przegląd Epidemiologiczny</i> , <b>2015</b> , 69, 27-31, 135-8	0.4	1
22	Recommendations for elastography-based imaging of liver. <i>Przegląd Epidemiologiczny</i> , <b>2015</b> , 69, 317-21, 429-33	0.4	2
21	DRESS syndrome as a complication of treatment of hepatitis C virus-associated post-inflammatory liver cirrhosis with peginterferon $\alpha$ 2a and ribavirin. <i>Postępy Dermatologii i Alergologii</i> , <b>2014</b> , 31, 401-4	1.5	2
20	Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 235-43	1.6	7
19	Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 245-57	1.6	19
18	Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment. <i>Journal of Medical Virology</i> , <b>2013</b> , 85, 441-8	19.7	12
17	Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. <i>Antiviral Research</i> , <b>2013</b> , 97, 312-7	10.8	15
16	Case report of African tick-bite fever from Poland. <i>Postępy Dermatologii i Alergologii</i> , <b>2013</b> , 30, 396-8	1.5	4
15	Distribution of HCV genotypes in Poland. <i>Przegląd Epidemiologiczny</i> , <b>2013</b> , 67, 11-6, 99-103	0.4	17
14	Surveillance programmes for early detection of hepatocellular carcinoma. <i>Współczesna Onkologia</i> , <b>2012</b> , 16, 295-9	1	2
13	Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , <b>2012</b> , 56, 67-75	11.2	64

12	Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon- $\beta$ 2b: relation to response and HBV genotype. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 9-17	1.6	54
11	Picolinic acid in patients with chronic hepatitis C infection: a preliminary report. <i>Mediators of Inflammation</i> , <b>2012</b> , 2012, 762863	4.3	7
10	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon $\beta$ -2a: progressive decrease in hepatitis B surface antigen in responders. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 1012-9	2.2	10
9	Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 633-42	1.6	6
8	Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures. <i>Hepatitis Monthly</i> , <b>2012</b> , 12, 32-7	1.8	37
7	Prevalence and risk factors of HCV infection in Poland. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 1213-7	2.2	46
6	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , <b>2011</b> , 31 Suppl 2, 30-60	7.9	293
5	A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1762-9	0.7	71
4	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , <b>2010</b> , 52, 454-61	11.2	188
3	Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. <i>Gastroenterology</i> , <b>2008</b> , 135, 459-67	13.3	301
2	Retinol $\beta$ itamin A in HIV-infected patients who are former intravenous drug users. <i>Nutrition Research</i> , <b>2004</b> , 24, 427-434	4	1
1	Clinical and epidemiological assessment of hepatitis C virus infection among voluntary blood donors. <i>Medical Science Monitor</i> , <b>2002</b> , 8, CR591-6	3.2	2